Evidence map›Paper›PMID 42630438›Full record

ArticleNAR cancer2026

A complex mutational signature generated by cytarabine resistance.

Dengchao Cao, Mianmian Yin, Ryan Bertoli, Zhenhua Zhang, Allyson Lu, Jack Zhu, Timour Baslan, Yang Jo Chung, Vijay Negi, Paul Meltzer and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in NAR cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Dengchao CaoGenetics Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, United States.ORCID https://orcid.org/0000-0001-9808-991X
Mianmian YinGenetics Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, United States.ORCID https://orcid.org/0000-0001-5573-8991
Ryan BertoliGenetics Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, United States.
Zhenhua ZhangGenetics Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, United States.
Allyson LuGenetics Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, United States.
Jack ZhuGenetics Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, United States.
Timour BaslanDepartment of Biomedical Sciences, The School of Veterinary Medicine, The University of Pennsylvania, Philadelphia, PA 19104, United States.
Yang Jo ChungGenetics Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, United States.
Vijay NegiGenetics Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, United States.
Paul MeltzerGenetics Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, United States.ORCID https://orcid.org/0000-0003-0963-1768
Peter D AplanGenetics Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, United States.ORCID https://orcid.org/0000-0001-5686-9969

Funding

Activation of Proto-Oncogenes by Chromosomal TranslocationZIASC010378 · NCI · DIVISION OF CLINICAL SCIENCES - NCI · PI APLAN, PETER · 2009 to 2025
$8.4M
Pre-clinical Studies of Therapy for Myelodysplastic SyndromeZIABC010983 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI APLAN, PETER · 2009 to 2025
$8.2M
Intramural NIH HHS ZIA BC010983Intramural NIH HHS ZIA SC010378
6 · The paper itself

Abstract

T-cell acute lymphoblastic leukemia (T-ALL) patients generally respond well to chemotherapy, but T-ALL cells at relapse are typically resistant to chemotherapy. The specific mechanisms leading to chemoresistance are incompletely understood. We used

Indexed as

Antimetabolites, AntineoplasticCytarabineDrug Resistance, NeoplasmMutationPrecursor T-Cell Lymphoblastic Leukemia-LymphomaCell Line, TumorCell ProliferationDeoxycytidine KinaseDNA Copy Number VariationsHumansTumor Suppressor Protein p53Antimetabolites, AntineoplasticCytarabineDeoxycytidine KinaseTumor Suppressor Protein p53

Identifiers

PMID42630438
PMCPMC13494411

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.